4.87  -0.12 (-2.4%)		09-18 16:00
Open: 5 High: 5.09 Volume: 343,247		Pre. Close: 4.99 Low: 4.85 Market Cap: 270(M)

Short term
Mid term
Targets	6-month :	6.41	1-year :	7.48
Resists	First :	5.48	Second :	6.41
Pivot price	4.89
Supports	First :	4.64	Second :	4.11
MAs	MA(5) :	5.09	MA(20) :	4.79
	MA(100) :	4.18	MA(250) :	2.5
MACD	MACD :	0.1	Signal :	0.1
%K %D	K(14,3) :	64.4	D(3) :	72.5
RSI	RSI(14): 52.9
52-week	High :	6.09	Low :	0.72

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ RZLT ] has closed above bottom band by 47.9%. Bollinger Bands are 13.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	5.1 - 5.13	5.13 - 5.15
Low:	4.78 - 4.82	4.82 - 4.85
Close:	4.82 - 4.88	4.88 - 4.92

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Sun, 15 Sep 2024
Federated Hermes Inc. Acquires 1,125,000 Shares of Rezolute, Inc. (NASDAQ:RZLT) - MarketBeat

Thu, 12 Sep 2024
Brokerages Set Rezolute, Inc. (NASDAQ:RZLT) Price Target at $10.75 - MarketBeat

Tue, 10 Sep 2024
Rezolute Gains 13%, Insider Trades Reap Benefit - Simply Wall St

Mon, 09 Sep 2024
FDA Gives Green Signal To Rezolute's Genetic Disorder Treatment - Benzinga

Mon, 09 Sep 2024
Rezolute rises as FDA lifts clinical hold on hyperinsulinism therapy (NASDAQ:RZLT) - Seeking Alpha

Tue, 27 Aug 2024
Rezolute to Participate in Upcoming Investor Conferences - StockTitan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	55 (M)
Shares Float	31 (M)
Held by Insiders	12.3 (%)
Held by Institutions	77.2 (%)
Shares Short	1,260 (K)
Shares Short P.Month	1,310 (K)

EPS	-1.14
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.76
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-34.7 %
Return on Equity (ttm)	-58.8 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.12
Qtrly Earnings Growth	0 %
Operating Cash Flow	-50 (M)
Levered Free Cash Flow	-28 (M)

PE Ratio	-4.28
PEG Ratio	0
Price to Book value	2.75
Price to Sales	0
Price to Cash Flow	-5.38

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.